Photo of Gregory A. Morris, Ph.D.Photo of Gregory A. Morris, Ph.D.

Gregory A. Morris, Ph.D.

Partner
Leader, Life Sciences Intellectual Property Litigation Practice Group

Education

Fordham University School of Law, J.D.
  • Fordham Intellectual Property Media & Entertainment Law Journal, Associate Editor
Northwestern University, Ph.D.
  • Organic Chemistry
University of Michigan, B.A.
  • English Literature

Prior Experience

  • Kirkland & Ellis LLP, Partner
  • Fish & Neave LLP, Associate/Patent Agent

Admissions

Court Admissions

Bar & Community Involvement

Intellectual Property Owners Association

New York Intellectual Property Law Association

The Richard Linn American Inn of Court

Overview
Experience
News & Resources
Honors

Overview

Gregory is the Leader of Honigman's Life Sciences Intellectual Property Litigation Practice Group. He holds a Ph.D. in Organic Chemistry from Northwestern University. Gregory’s practice focuses on pharmaceutical, biotechnology, and medical device patent litigation. He has extensive experience representing top pharmaceutical clients on the brand-side in Hatch-Waxman litigation. Gregory also regularly litigates inter partes review (IPR) proceedings before the US Patent and Trademark Office (USPTO).  He co-led a team of attorneys who represented a pharmaceutical company in the first-ever successful defense of an Orange Book-listed patent in an IPR review.

Gregory was recognized in the Crain’s Chicago Business 2019 list of “Notable Gen X Leaders in Law.” He has also been named a Patent Star by Managing IP every year since 2016 and a Life Sciences Star by LMG Life Sciences every year since 2017 for general patent litigation, patent strategy and management, and Hatch-Waxman Patent Litigation. Gregory has been quoted extensively in the media and writes and lectures widely on Hatch-Waxman litigation, biologics, and the PTAB.

Experience

Significant representative matters include:

  • Ironwood Pharmaceuticals, Allergan, and Forest Laboratories

    Lead counsel for Ironwood Pharmaceuticals in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug, Linzess®.  Obtained consent judgments with injunctions against all defendants. (D. Del.) (Jan. 2020)
  • Merck and 3M
    Represented Merck and 3M in patent infringement litigation filed by AptarGroup relating to Merck’s prescription asthma product, Dulera®.  Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice.  (PTAB) (Nov. 2019) (N.D. Ill.) (Jan. 2020)
  • Ironwood Pharmaceuticals
    Lead counsel for Ironwood Pharmaceuticals in IPR proceeding where Synergy Pharmaceuticals challenged client’s patent related to peptide therapeutics for the treatment of gastrointestinal disorders, obtaining an order terminating the proceedings.  (PTAB) (Nov. 2018)
  • Merck
    Co-lead counsel for Merck in IPR action against Apotex who was seeking to challenge a patent protecting Merck’s prescription product, Emend®.  Obtained a win whereby the institution of the IPR proceeding was denied.  (PTAB) (Oct. 2015)*
  • Galderma Labs. and Supernus Pharmaceuticals
    Represented Galderma and Supernus in parallel IPRs and Hatch-Waxman patent infringement litigation to protect clients’ prescription rosacea drug, Oracea®.  Co-led team that obtained IPR win after final written decision that was the first-ever successful defense of an Orange Book-listed patent in an IPR review. Obtained consent judgments with injunctions against all defendants.  (PTAB) (D. Del.)*  
  • Sanofi
    Represented Sanofi in Hatch-Waxman patent infringement litigation to protect client’s prescription digestive drug, Uroxatral ®.  Obtained a bench trial verdict at the close of evidence finding infringement and upholding the validity of the patents.  Obtained consent judgments with injunctions against all defendants.  (D. Del.)* 
  • Alexion Pharmaceuticals
    Represented Alexion in patent infringement litigation brought by PDL involving client's humanized antibody drug, Soliris®, obtaining a dismissal of all claims.  (D. Del.)* 
  • Forest Laboratories and Lundbeck A/S
    Represented Forest and Lundbeck in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug, Lexapro®.  Obtained consent judgments with injunctions against all defendants after bench trial.  (D. Del.)*

* Matter handled prior to joining Honigman

News & Resources

Publications

Seminars & Events

Honors

  • Crain’s Chicago Business Notable Gen X Leaders in Law, 2019
  • LMG Life Sciences, Recognized as a Life Sciences Star, 2017-2019
    • Recognized for General Patent Litigation, Patent Strategy & Management, Hatch-Waxman Patent Litigation
  • Managing Intellectual Property IP STARS, Recognized as a Patent Star, 2016-2020